Pediatric uveitis

小儿葡萄膜炎

• 批准号: 7322368
• 负责人: Janine A Smith
• 金额: --
• 依托单位: NATIONAL EYE INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7322368
• 关键词: Pediatric; uveitis

The NEI intramural clinical research program includes study of the evaluation and treatment of children with uveitis. Childhood uveitis is distinct from adult disease in the specific disease entities which predominate, the course (may be more aggressive than in adults) and range of appropriate therapies and children present unique challenges to treatment of ocular inflammatory disease including amblyopia risk and growth retardation as a complication of corticosteroid treatment. Few studies have comprehesively addressed pediatric uveitis to quantify the problem, describe the proportion of affected children with visual impairment and blindness or identify prognostic factors and ascertain the children most at risk for poor outcome. Ongoing clinical studies include the evaluation and treatment of children with uveitis, with a specific protocol (05-EI-0208) to evaluate the safety and explore the efficacy of a novel approach using daclizumab (anti-IL-2R Mab)treatment for anterior uveitis associated with juvenile idiopathic arthritis, a particularly severe disease and the most common systemic disease associated with pediatric uveitis.

NEI壁内临床研究计划包括研究葡萄膜炎儿童的评估和治疗。儿童葡萄膜炎在特定疾病实体中与成人疾病不同，这些特定疾病是占主导地位的，该病程（可能比成人更具侵略性），适当的疗法和儿童对治疗眼炎性疾病的治疗带来了独特的挑战，包括弱视风险和增长迟缓，作为皮质类固醇治疗的并发症。很少有研究能够理解研究小儿葡萄膜炎来量化该问题，描述受影响的儿童患有视觉障碍和失明的比例，或者识别预后因素，并确定结果最有可能出现不良结果的儿童。正在进行的临床研究包括对葡萄膜炎儿童的评估和治疗，具有特定方案（05-EI-0208），以评估安全性并探索使用Daclizumab（Anti-IL-2R MAB）治疗一种新方法的疗效（抗IL-2R MAB）对前静脉炎，与少年性疾病疾病和最常见的系统性疾病相关的葡萄膜性疾病和最常见的系统性疾病有关。